Literature DB >> 35084654

Cortical Dysplasia in Rats Provokes Neurovascular Alterations, GLUT1 Dysfunction, and Metabolic Disturbances That Are Sustained Post-Seizure Induction.

Chaitali Ghosh1,2, Rosemary Myers3, Christina O'Connor4, Sherice Williams3, Xuefeng Liu5, Mohammed Hossain3, Michael Nemeth4, Imad M Najm4.   

Abstract

Focal cortical dysplasia (FCD) is associated with blood-brain barrier (BBB) dysfunction in patients with difficult-to-treat epilepsy. However, the underlying cellular and molecular factors in cortical dysplasia (CD) associated with progressive neurovascular challenges during the pro-epileptic phase, post-seizure, and during epileptogenesis remain unclear. We studied the BBB function in a rat model of congenital (in utero radiation-induced, first hit) CD and longitudinally examined the cortical brain tissues at baseline and the progressive neurovascular alterations, glucose transporter-1 (GLUT1) expression, and glucose metabolic activity at 2, 15, and 30 days following a second hit using pentylenetetrazole-induced seizure. Our study revealed through immunoblotting, immunohistochemistry, and biochemical analysis that (1) altered vascular density and prolongation of BBB albumin leakages in CD rats continued through 30 days post-seizure; (2) CD brain tissues showed elevated matrix metalloproteinase-9 levels at 2 days post-seizure and microglial overactivation through 30 days post-seizure; (3) BBB tight junction protein and GLUT1 levels were decreased and neuronal monocarboxylate transporter-2 (MCT2) and mammalian target of rapamycin (mTOR) levels were increased in the CD rat brain: (4) ATPase activity is elevated and a low glucose/high lactate imbalance exists in CD rats; and (5) the mTOR pathway is activated and MCT2 levels are elevated in the presence of high lactate during glucose starvation in vitro. Together, this study suggests that BBB dysfunction, including decreased GLUT1 expression and metabolic disturbance, may contribute to epileptogenesis in this CD rat model through multiple mechanisms that could be translated to FCD therapy in medically refractory epilepsy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Blood-brain barrier; Epilepsy; Glucose transporter-1; Monocarboxylate transporter-2; Tight junction proteins; mTOR

Mesh:

Substances:

Year:  2022        PMID: 35084654      PMCID: PMC9018620          DOI: 10.1007/s12035-021-02624-2

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  53 in total

Review 1.  Epilepsy: a review of selected clinical syndromes and advances in basic science.

Authors:  Carl E Stafstrom
Journal:  J Cereb Blood Flow Metab       Date:  2006-01-25       Impact factor: 6.200

Review 2.  The blood-brain barrier in health and chronic neurodegenerative disorders.

Authors:  Berislav V Zlokovic
Journal:  Neuron       Date:  2008-01-24       Impact factor: 17.173

Review 3.  Structure and function of the blood-brain barrier.

Authors:  N Joan Abbott; Adjanie A K Patabendige; Diana E M Dolman; Siti R Yusof; David J Begley
Journal:  Neurobiol Dis       Date:  2009-08-05       Impact factor: 5.996

Review 4.  The search for circulating epilepsy biomarkers.

Authors:  Manu Hegde; Daniel H Lowenstein
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

5.  A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage.

Authors:  Y Imai; I Ibata; D Ito; K Ohsawa; S Kohsaka
Journal:  Biochem Biophys Res Commun       Date:  1996-07-25       Impact factor: 3.575

6.  Temporal changes in mRNA expression of the brain nutrient transporters in the lithium-pilocarpine model of epilepsy in the immature and adult rat.

Authors:  Claire Leroy; Karin Pierre; Ian A Simpson; Luc Pellerin; Susan J Vannucci; Astrid Nehlig
Journal:  Neurobiol Dis       Date:  2011-05-23       Impact factor: 5.996

7.  Glut1 deficiency (G1D): epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype.

Authors:  Isaac Marin-Valencia; Levi B Good; Qian Ma; Joao Duarte; Teodoro Bottiglieri; Christopher M Sinton; Charles W Heilig; Juan M Pascual
Journal:  Neurobiol Dis       Date:  2012-04-23       Impact factor: 5.996

8.  Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy.

Authors:  Jae Seok Lim; Woo-il Kim; Hoon-Chul Kang; Se Hoon Kim; Ah Hyung Park; Eun Kyung Park; Young-Wook Cho; Sangwoo Kim; Ho Min Kim; Jeong A Kim; Junho Kim; Hwanseok Rhee; Seok-Gu Kang; Heung Dong Kim; Daesoo Kim; Dong-Seok Kim; Jeong Ho Lee
Journal:  Nat Med       Date:  2015-03-23       Impact factor: 53.440

9.  Neurovascular Drug Biotransformation Machinery in Focal Human Epilepsies: Brain CYP3A4 Correlates with Seizure Frequency and Antiepileptic Drug Therapy.

Authors:  Sherice Williams; Mohammed Hossain; Lisa Ferguson; Robyn M Busch; Nicola Marchi; Jorge Gonzalez-Martinez; Emilio Perucca; Imad M Najm; Chaitali Ghosh
Journal:  Mol Neurobiol       Date:  2019-06-26       Impact factor: 5.590

10.  Blood-brain barrier disruption in post-traumatic epilepsy.

Authors:  O Tomkins; I Shelef; I Kaizerman; A Eliushin; Z Afawi; A Misk; M Gidon; A Cohen; D Zumsteg; A Friedman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-11-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.